{"source_content":"请务必阅读正文之后的重要声明部分[Table_Industry]证券研究报告/专题研究报告2020年11月03日医药生物医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好[Table_Main][Table_Title]评级：增持（维持）分析师江琦执业证书编号：S0740517010002电话：021-20315150Email：jiangqi@r.qlzq.com.cn分析师：谢木青执业证书编号：S0740518010004Email：xiemq@r.qlzq.com.cn研究助理：李建Email：lijian01@r.qlzq.com.cn[Table_Profit]基本状况上市公司数78行业总市值(亿元)19,636.99行业流通市值(亿元)10,224.40[Table_QuotePic]行业-市场走势对比公司持有该股票比例[Table_Report]相关报告国家级冠脉支架集采落地，头部企业有望受益-江琦/谢木青-20201018迈瑞医疗（300760）：业绩超预期，诊断、彩超业务快速恢复-买入（维持）-江琦/谢木青-20201029蓝帆医疗（002382）：疫情下手套利润释放，心血管业务短期继续承压，长期看创新器械进入收获-买入（维持）-江琦/谢木青-20201028[Table_Finance]重点公司基本状况简称股价(元)EPSPEPEG评级20192020E2021E2022E20192020E2021E2022E迈瑞医疗405.313.855.516.537.98105.2773.5462.0750.763.61买入安图生物178.201.801.943.023.9099.1291.6859.0345.731.80买入南微医学212.092.282.083.284.4093.15101.7364.7148.182.25买入三友医疗53.390.480.530.751.01112.07100.5870.7352.962.66买入欧普康视70.660.510.650.881.13139.82108.9080.6562.553.41买入备注：截至日期2020/11/3[Table_Summary]投资要点2020年三季报收官，医疗器械行业延续上半年的高增长，且较上半年进一步加速，其中新冠疫情相关品种需求持续旺盛奠定高增长基础，国内疫情常态化后的快速恢复带来增长加速。2020Q3（前三季度，下同）医疗器械板块上市公司收入增速52.62%（+31.98pp），净利润总额增长134.51%（+99.83pp），扣非增长176.48%（+155.21pp）。Q3板块收入利润增速同比延续上半年的高增长，且进一步加速。具体细分子板块来看，2020Q3扣非增速从高到低排序为低值耗材、体外诊断、医疗设备、高值耗材，与上半年顺序一致。低值耗材：疫情下口罩、手套个股带动板块业绩高增长。低值耗材板块（19.84%，373.81%，506.13%，依次为2019年前三季度、2020年上半年、2020前三季度扣非增速，下同）Q3延续高增长态势，扣非利润同比增长506.13%（+486.29pp）；期间费用率下降，为16.15%（-9.19pp）；盈利能力大幅提高，毛利率53.60%（+13.40pp），净利率31.04%（+18.71pp）。主要系疫情下口罩、手套等疫情相关耗材带动利润规模大幅增长所致，如英科医疗（手套，+3429.38%，扣非增速，下同）、振德医疗（口罩，+3072.74%）、阳普医疗（真空采血管，+1410.80%）、蓝帆医疗（手套，+442.40%）、奥美医疗（口罩，+356.79%）等。考虑到不同种类防疫产品生产技术壁垒、产线建设周期等各不相同，我们看好中期景气度较高的手套板块，建议重点关注相关优质企业英科医疗、蓝帆医疗等。体外诊断：新冠检测贡献增量，常规业务逐步恢复。体外诊断板块（39.30%，214.09%，208.36%）Q3延续高增长，扣非利润同比增长208.36%（+169.06pp）；期间费用率下降，为25.58%（-6.81pp）；整体盈利能力提升，毛利率60.22%（+7.77pp），净利率29.08%（+13.03pp）。一方面，高毛利的新冠检测产品+服务贡献业绩增量；另一方面，国内疫情受控下，企业顺利复工复产，医院诊疗量逐步恢复，常规检测业务陆续恢复。综合考虑竞争格局、常规业务恢复进度，我们看好两条投资方向：1）ICL，行业竞争格局清晰，新冠检测量在防控常态化下有望中期保持高位，传统外包持续恢复，建议重点关注金域医学、迪安诊断；2）化学发光板块，疫情期间头部企业装机持续加速，随着诊疗人次回升，业绩有望加速恢复，建议重点关注安图生物、迈瑞医疗、新产业。医疗设备：医用场景呼吸机、监护仪需求持续旺盛，消费场景家用器械快速恢复。医疗设备板块（20.25%，88.29%，86.26%）Q3延续上半年的高增长，扣非利润同比增长86.26%（+66.01pp）；期间费用率略降，为-40%-20%0%20%40%60%80%18-0718-1019-0119-0419-0719-1020-0120-0420-0720-10医药生物(申万)沪深300请务必阅读正文之后的重要声明部分-2-专题研究报告26.57%（-2.42pp）；盈利能力增强，毛利率53.51%（+5.85pp），净利率23.68%（+5.09pp）。医用场景下受国内疫情防控及海外疫情反复带来国际市场对抗疫设备如呼吸机、监护仪、红外额温枪、输注泵等需求持续旺盛带动，企业相关产品销售量维持高位；消费场景下，血糖、血压计等家用器械产品销售从疫情影响之中加速恢复。长期来说，疫情后公卫支出有望大幅提升，医用设备有望受益于医院ICU、呼吸科、传染科、检验科等科室的加速建设；而家用设备持续保持消费升级与智能升级双轮驱动。看好相关优质企业如迈瑞医疗、鱼跃医疗等。高值耗材：Q3加速恢复，看好第四季度及明年持续复苏。高值耗材板块（44.78%，17.00%，26.37%）Q3增速同比放缓，扣非利润同比26.37%（-18.41pp），但相比上半年恢复显著（+9.37pp）；期间费用率略降，为38.76%（-2.73pp）；盈利能力基本维持稳定，毛利率71.29%（-0.98pp），净利率30.65%（+2.92pp）。随着国内疫情受控，企业复工复产顺利进行，医院门诊、手术量逐步恢复常态，板块在第三季度加速恢复，我们看好第四季度及明年持续复苏。整体板块受支架带量采购政策负面情绪影响短期有所调整，我们认为未来企业需要通过持续创新来抵御单品种降价风险，我们看好创新能力强的头部企业，如微创医疗、乐普医疗、蓝帆医疗、三友医疗等。投资建议：医疗器械行业当前正处于黄金发展期，高壁垒化升级带来的进口替代以及消费化升级仍然是目前国内医疗器械两大发展方向，疫情虽然短期对行业内各企业带来不同影响，但行业长期趋势并未发生改变。我们一方面建议重点关注具备强产品研发能力和技术实力的企业，包括迈瑞医疗、安图生物、南微医学、三友医疗、微创医疗等，另一方面建议重点关注具备强消费属性的产品企业，包括欧普康视、伟思医疗等。风险提示：产品市场推广不达预期风险，政策变化风险等。请务必阅读正文之后的重要声明部分-3-专题研究报告内容目录海外防疫产品需求持续旺盛，国内恢复趋势良好................................................-4-低值耗材：疫情下口罩、手套带动板块业绩高增长，手套有望迎来量价齐升-6-体外诊断：新冠检测贡献增量，常规业务逐步恢复....................................-7-医疗设备：医用场景呼吸机、监护仪需求持续旺盛，消费场景家用器械快速恢复...................-8-高值耗材：Q3加速恢复，看好第四季度及明年持续复苏...........................-9-投资建议............................................................................................................-11-图表目录图表1：医疗器械各细分板块营收累计同比增长表.............................................-4-图表2：医疗器械各细分板块营收累计同比增长图.............................................-4-图表3：医疗器械各细分板块净利润总额累计同比增长表..................................-4-图表4：医疗器械各细分板块净利润总额累计同比增长图..................................-4-图表5：医疗器械各细分板块扣非利润累计同比增长表.....................................-5-图表6：医疗器械各细分板块扣非利润累计同比增长图.....................................-5-图表7：A股医疗器械板块2020Q3盈利增长情况.............................................-5-图表8：A股医疗器械板块2020Q3期间费用率情况.........................................-5-图表9：A股医疗器械板块2020Q3期间财务比率情况.....................................-6-图表10：A股医疗器械板块2020Q3毛利率、净利率及经营现金流情况..........-6-图表11：低值耗材板块业绩表现及盈利能力......................................................-7-图表12：体外诊断板块业绩表现及盈利能力......................................................-8-图表13：医疗设备板块业绩表现及盈利能力......................................................-9-图表14：高值耗材板块业绩表现及盈利能力....................................................-10-图表15：高值耗材板块分季度归母净利润增速情况.........................................-10-请务必阅读正文之后的重要声明部分-4-专题研究报告海外防疫产品需求持续旺盛，国内恢复趋势良好我们统计了A股医疗器械板块上市公司的2020年三季报情况，按照主营业务比重进行划分，将板块分为医疗设备、高值耗材、体外诊断、低值耗材等四个细分子板块，总计78家上市公司。2020年三季报收官，医疗器械行业延续上半年的高增长，且较上半年进一步加速，其中新冠疫情相关品种需求持续旺盛奠定高增长基础，国内疫情常态化后的快速恢复带来增长加速。2020Q3（文中Q3均指前三季度）医疗器械板块上市公司收入增速52.62%（+31.98pp），净利润总额增长134.51%（+99.83pp），扣非净利润增长176.48%（+155.21pp）。Q3板块收入利润增速同比延续上半年的高增长，且进一步加速。具体细分子板块来看，2020Q3扣非增速从高到低排序为低值耗材、体外诊断、医疗设备、高值耗材，与上半年顺序一致。图表1：医疗器械各细分板块营收累计同比增长表图表2：医疗器械各细分板块营收累计同比增长图来源：Wind，中泰证券研究所来源：Wind，中泰证券研究所图表3：医疗器械各细分板块净利润总额累计同比增长表图表4：医疗器械各细分板块净利润总额累计同比增长图来源：Wind，中泰证券研究所来源：Wind，中泰证券研究所19H119Q319A20Q120H120Q3医疗器械24.06%20.65%14.40%5.25%42.23%52.62%低值耗材17.77%17.02%16.83%16.35%93.96%124.27%高值耗材55.42%32.02%25.91%-10.01%8.80%11.97%体外诊断30.16%27.97%15.50%2.24%49.16%59.96%医疗设备11.35%10.97%8.35%8.35%27.09%30.42%营业收入-20.00%0.00%20.00%40.00%60.00%80.00%100.00%120.00%140.00%18Q118H118Q318A19Q119H119Q319A20Q120H120Q3医疗器械低值耗材高值耗材体外诊断医疗设备19H119Q319A20Q120H120Q3医疗器械42.63%34.67%16.08%4.01%102.35%134.51%低值耗材23.37%22.66%30.23%42.26%337.58%464.71%高值耗材59.40%36.12%12.55%-22.95%8.64%23.77%体外诊断39.71%40.43%-2.38%17.75%161.39%189.81%医疗设备40.35%31.87%31.79%0.86%58.19%66.13%净利润总额-100.00%0.00%100.00%200.00%300.00%400.00%500.00%18Q118H118Q318A19Q119H119Q319A20Q120H120Q3医疗器械低值耗材高值耗材体外诊断医疗设备请务必阅读正文之后的重要声明部分-5-专题研究报告图表5：医疗器械各细分板块扣非利润累计同比增长表图表6：医疗器械各细分板块扣非利润累计同比增长图来源：Wind，中泰证券研究所来源：Wind，中泰证券研究所图表7：A股医疗器械板块2020Q3盈利增长情况来源：Wind，中泰证券研究所疫情导致销售、管理费用率小幅下降。2020Q3医疗器械板块销售费用率13.34%（-4.08pp），管理费用率（含研发费用）11.06%（-2.73pp），财务费用率0.84%（+0.48pp），销售、管理费用率同比小幅下降预计为疫情下市场推广费、差旅费等减少所致。图表8：A股医疗器械板块2020Q3期间费用率情况来源：Wind，中泰证券研究所资产负债率保持稳定，资产周转情况良好。2020Q3医疗器械板块资产负债率30.84%（-2.57pp），基本保持稳定；应收账款周转率3.53次（+0.77次），存货周转率1.90次（-0.10次），资产周转情况良好。19H119Q319A20Q120H120Q3医疗器械31.52%21.27%13.80%24.04%134.28%176.48%低值耗材32.37%19.84%24.97%59.73%373.81%506.13%高值耗材63.34%44.78%15.00%-0.71%17.00%26.37%体外诊断24.86%39.30%0.60%17.27%214.09%208.36%医疗设备19.43%20.25%21.12%32.46%88.29%86.26%扣非净利润-100.00%0.00%100.00%200.00%300.00%400.00%500.00%600.00%17A18Q118H118Q318A19Q119H119Q319A20Q120H120Q3医疗器械低值耗材高值耗材体外诊断医疗设备19Q320Q3增速变化19Q320Q3增速变化医疗器械20.65%52.62%31.98%21.27%176.48%155.21%低值耗材17.02%124.27%107.26%19.84%506.13%486.29%高值耗材32.02%11.97%-20.05%44.78%26.37%-18.41%体外诊断27.97%59.96%31.99%39.30%208.36%169.06%医疗设备10.97%30.42%19.44%20.25%86.26%66.01%扣除非经常性损益的净利润增速主要子板块营业收入增速主要子板块19Q320Q3同比变化19Q320Q3同比变化19Q320Q3同比变化医疗器械17.42%13.34%-4.08%13.79%11.06%-2.73%0.36%0.84%0.48%低值耗材13.39%8.07%-5.32%11.38%7.07%-4.31%0.57%1.01%0.44%高值耗材25.11%22.51%-2.60%15.24%15.65%0.41%1.14%0.60%-0.53%体外诊断16.84%13.33%-3.52%14.70%11.24%-3.46%0.85%1.02%0.17%医疗设备16.18%13.89%-2.29%13.31%12.19%-1.11%-0.50%0.49%0.99%销售费用率管理费用率（含研发费用）财务费用率请务必阅读正文之后的重要声明部分-6-专题研究报告图表9：A股医疗器械板块2020Q3期间财务比率情况来源：Wind，中泰证券研究所盈利能力增强，经营性现金流大幅提升。2020Q3医疗器械板块毛利率58.50%（+5.99pp），净利率28.54%（+9.97pp），盈利能力增强。其中低值耗材、体外诊断、医疗设备的毛利率、净利率均有一定提升，高值耗材基本保持稳定。板块整体的经营现金流为405.31亿元（+210.78%），同比大幅提升，我们预计主要是防疫产品预付款提升的原因。图表10：A股医疗器械板块2020Q3毛利率、净利率及经营现金流情况来源：Wind，中泰证券研究所低值耗材：疫情下口罩、手套带动板块业绩高增长，手套有望迎来量价齐升低值耗材：疫情下口罩、手套个股带动板块业绩高增长。低值耗材板块（19.84%，373.81%，506.13%，依次为2019年前三季度、2020年上半年、2020前三季度扣非增速，下同）Q3延续高增长态势，扣非利润同比增长506.13%（+486.29pp）；期间费用率下降，为16.15%（-9.19pp）；盈利能力大幅提高，毛利率53.60%（+13.40pp），净利率31.04%（+18.71pp）。主要系疫情下口罩、手套等疫情相关耗材带动利润规模大幅增长所致，如英科医疗（手套，+3429.38%，扣非增速，下同）、振德医疗（口罩，+3072.74%）、阳普医疗（真空采血管，+1410.80%）、蓝帆医疗（手套，+442.40%）、奥美医疗（口罩，+356.79%）等。考虑到不同种类防疫产品生产技术壁垒、产线建设周期等各不相同，我们看好中期景气度较高的手套板块，建议重点关注相关优质企业英科医疗、蓝帆医疗等。主要子板块19Q320Q3同比变化19Q320Q3同比变化（次）19Q320Q3同比变化（次）医疗器械33.41%30.84%-2.57%2.763.530.772.001.90(0.10)低值耗材33.57%34.76%1.18%3.536.372.842.393.060.68高值耗材31.78%25.75%-6.03%2.993.030.041.621.27(0.35)体外诊断32.68%31.23%-1.45%2.082.280.202.342.03(0.31)医疗设备36.10%33.01%-3.09%3.234.721.491.971.69(0.28)资产负债率应收账款周转率存货周转率主要子板块19Q320Q3同比变化19Q320Q3同比变化19Q320Q3同比增长医疗器械52.51%58.50%5.99%18.58%28.54%9.97%1304240531210.78%低值耗材40.21%53.60%13.40%12.33%31.04%18.71%196112068515.28%高值耗材72.27%71.29%-0.98%27.73%30.65%2.92%3009410636.48%体外诊断52.44%60.22%7.77%16.05%29.08%13.03%345912305255.78%医疗设备47.66%53.51%5.85%18.59%23.68%5.09%456312621176.61%净利率毛利率经营性现金流（百万元）请务必阅读正文之后的重要声明部分-7-专题研究报告图表11：低值耗材板块业绩表现及盈利能力来源：Wind，中泰证券研究所体外诊断：新冠检测贡献增量，常规业务逐步恢复体外诊断：新冠检测贡献增量，常规业务逐步恢复。体外诊断板块（39.30%，214.09%，208.36%）Q3延续高增长，扣非利润同比增长208.36%（+169.06pp）；期间费用率下降，为25.58%（-6.81pp）；整体盈利能力提升，毛利率60.22%（+7.77pp），净利率29.08%（+13.03pp）。一方面，高毛利的新冠检测产品+服务贡献业绩增量；另一方面，国内疫情受控下，企业顺利复工复产，医院诊疗量逐步恢复，常规检测业务陆续恢复。综合考虑竞争格局、常规业务恢复进度，我们看好两条投资方向：1）ICL，行业竞争格局清晰，新冠检测量在防控常态化下有望中期保持高位，传统外包持续恢复，建议重点关注金域医学、迪安诊断；2）化学发光板块，疫情期间头部企业装机持续加速，随着诊疗人次回升，业绩有望加速恢复，建议重点关注安图生物、迈瑞医疗、新产业。19Q320Q3同比变化19Q320Q3同比变化19Q320Q3同比变化300677.SZ英科医疗2.77%3429.38%3426.62%24.42%68.52%44.10%8.25%48.88%40.63%603301.SH振德医疗25.51%3072.74%3047.23%31.88%46.47%14.59%8.10%29.69%21.60%300030.SZ阳普医疗74.00%1410.80%1336.80%43.46%48.51%5.05%5.56%33.48%27.92%002382.SZ蓝帆医疗25.76%442.40%416.64%45.98%62.82%16.84%15.24%40.66%25.42%002950.SZ奥美医疗56.03%356.79%300.76%33.41%43.75%10.34%12.66%31.10%18.44%603880.SH南卫股份-8.44%184.94%193.37%23.21%33.40%10.19%9.16%10.17%1.01%603309.SH维力医疗117.05%74.20%-42.85%43.54%45.89%2.36%14.74%17.23%2.49%600529.SH山东药玻27.82%20.89%-6.93%37.09%38.22%1.14%15.82%17.92%2.11%603987.SH康德莱7.55%20.47%12.92%36.71%38.25%1.55%13.94%12.94%-1.01%603976.SH正川股份-31.99%-18.07%13.92%26.69%25.94%-0.75%12.19%11.71%-0.47%603367.SH辰欣药业6.73%-20.44%-27.17%56.86%59.39%2.53%13.74%12.23%-1.50%19.84%506.13%486.29%40.21%53.60%13.40%12.33%31.04%18.71%证券简称证券代码板块合计扣非净利润增速毛利率净利率请务必阅读正文之后的重要声明部分-8-专题研究报告图表12：体外诊断板块业绩表现及盈利能力来源：Wind，中泰证券研究所医疗设备：医用场景呼吸机、监护仪需求持续旺盛，消费场景家用器械快速恢复医疗设备：医用场景呼吸机、监护仪需求持续旺盛，消费场景家用器械快速恢复。医疗设备板块（20.25%，88.29%，86.26%）Q3延续上半年的高增长，扣非利润同比增长86.26%（+66.01pp）；期间费用率略降，为26.57%（-2.42pp）；盈利能力增强，毛利率53.51%（+5.85pp），净利率23.68%（+5.09pp）。医用场景下受国内疫情防控及海外疫情反复带来国际市场对抗疫设备如呼吸机、监护仪、红外额温枪、输注泵等需求持续旺盛带动，企业相关产品销售量维持高位；消费场景下，血糖、血压计等家用器械产品销售从疫情影响之中加速恢复。长期来说，疫情后公卫支出有望大幅提升，医用设备有望受益于医院ICU、呼吸科、传染科、检验科等科室的加速建设；而家用设备持续保持消费升级与智能升级双轮驱动。看好相关优质企业如迈瑞医疗、鱼跃医疗等。19Q320Q3同比变化19Q320Q3同比变化19Q320Q3同比变化688289.SH圣湘生物/15518.29%/64.44%82.19%17.75%7.66%55.83%48.17%002030.SZ达安基因11.82%2089.31%2077.49%51.49%69.03%17.54%8.89%42.19%33.30%688298.SH东方生物14.22%1139.63%1125.41%47.01%83.03%36.03%21.03%60.35%39.32%300676.SZ华大基因-14.71%1066.14%1080.85%55.62%64.61%8.99%13.00%40.46%27.46%688399.SH硕世生物49.04%1060.39%1011.35%82.12%81.14%-0.98%26.11%52.86%26.75%002932.SZ明德生物-20.30%890.80%911.10%76.90%81.44%4.54%32.83%56.31%23.48%603392.SH万泰生物/337.80%/71.24%80.28%9.04%15.09%29.42%14.33%603882.SH金域医学88.25%293.16%204.91%39.86%45.74%5.88%8.34%18.87%10.54%300639.SZ凯普生物38.44%167.12%128.69%81.19%76.40%-4.79%18.95%32.66%13.70%300244.SZ迪安诊断17.96%165.52%147.56%32.28%37.43%5.14%8.51%14.82%6.31%300482.SZ万孚生物36.66%97.92%61.25%65.22%71.54%6.33%21.75%26.11%4.36%605369.SH拱东医疗/89.88%/44.72%48.74%4.02%20.59%27.00%6.40%688389.SH普门科技82.12%54.10%-28.02%60.90%62.67%1.77%22.07%23.62%1.56%300463.SZ迈克生物17.42%35.80%18.38%52.76%53.37%0.60%18.92%23.27%4.35%300298.SZ三诺生物-2.81%21.54%24.35%65.89%65.44%-0.44%16.94%16.31%-0.63%300685.SZ艾德生物11.39%10.83%-0.55%90.32%87.39%-2.92%26.39%26.06%-0.33%688393.SH安必平/6.76%/84.18%81.10%-3.08%23.75%24.81%1.05%603387.SH基蛋生物9.30%2.64%-6.66%71.10%62.82%-8.27%32.53%29.08%-3.45%300832.SZ新产业/2.33%/80.01%78.06%-1.94%47.21%44.47%-2.74%300318.SZ博晖创新-82.97%-5.32%77.65%48.98%48.81%-0.17%1.87%0.90%-0.97%688338.SH赛科希德/-9.35%/59.91%59.61%-0.30%30.14%26.57%-3.57%300396.SZ迪瑞医疗23.65%-11.76%-35.40%65.24%58.59%-6.65%29.84%35.57%5.73%603658.SH安图生物31.32%-11.99%-43.31%66.64%60.20%-6.44%28.95%25.40%-3.55%300289.SZ利德曼-84.26%-18.42%65.84%54.91%54.84%-0.07%6.35%6.34%-0.01%300439.SZ美康生物1.85%-23.43%-25.27%35.56%38.40%2.83%9.49%16.93%7.43%000710.SZ贝瑞基因-5.95%-46.11%-40.16%59.13%52.49%-6.63%26.45%13.50%-12.95%300406.SZ九强生物11.41%-57.20%-68.62%68.30%60.63%-7.67%38.10%17.27%-20.83%300642.SZ透景生命13.52%-76.07%-89.59%78.61%65.25%-13.37%33.69%12.43%-21.26%688068.SH热景生物/-98.81%/72.54%68.47%-4.07%9.44%2.30%-7.14%39.30%208.36%169.06%52.44%60.22%7.77%16.05%29.08%13.03%净利率证券代码证券简称板块合计扣非净利润增速毛利率请务必阅读正文之后的重要声明部分-9-专题研究报告图表13：医疗设备板块业绩表现及盈利能力来源：Wind，中泰证券研究所高值耗材：Q3加速恢复，看好第四季度及明年持续复苏高值耗材：Q3加速恢复，看好第四季度及明年持续复苏。高值耗材板块（44.78%，17.00%，26.37%）Q3增速同比放缓，扣非利润同比26.37%（-18.41pp），但相比上半年恢复显著（+9.37pp）；期间费用率略降，为38.76%（-2.73pp）；盈利能力基本维持稳定，毛利率71.29%（-0.98%），净利率30.65%（+2.92pp）。随着国内疫情受控，企业复工复产顺利进行，医院门诊、手术量恢复常态，板块在第三季度加速恢复，归母净利润环比提速或保持快速增长或回正，如眼科的爱博医疗（-80.10%，74.70%，152.04%，依次为2020年第一季度、第二季度、第三季度归母净利润增速，下同）、欧普康视（-24.81%，36.05%，32.68%），心血管支架的乐普医疗（-34.13%，32.11%，82.28%）、心脉医疗（32.42%，52.28%，52.13%），以及骨科植入耗材的大博医疗（7.85%，40.31%，20.85%）、三友医疗（-39.18%，-12.52%，76.52%）、凯利泰（-30.79%，-14.80%，12.87%）等。国家级冠脉支架集采引领高值耗材全国带量采购进程，看好创新能力强的头部企业。国家级冠脉支架集采落地为其他品类的国家级集采奠定实施基础，起到示范效应。从规则上看，头部企业可通过降价保存量求增量来扩大市场份额，有望相对受益。集采降价对行业空间压制下，未来通过持续创新来抵御单品种降价风险方是良策，我们看好创新能力强的头部企业，如微创医疗、乐普医疗、蓝帆医疗、三友医疗等。19Q320Q3同比变化19Q320Q3同比变化19Q320Q3同比变化300869.SZ康泰医学/1375.30%/46.49%62.23%15.74%15.95%46.34%30.39%600587.SH新华医疗-77.05%696.94%774.00%21.76%23.55%1.79%12.85%3.42%-9.43%300206.SZ理邦仪器75.13%532.54%457.40%55.88%59.71%3.83%13.43%33.36%19.93%688301.SH奕瑞科技/390.00%/49.93%52.83%2.90%10.59%28.23%17.65%300314.SZ戴维医疗12.63%275.98%263.35%51.40%57.12%5.72%17.05%39.97%22.92%002551.SZ尚荣医疗-45.55%137.72%183.27%23.86%31.83%7.97%6.86%17.13%10.27%002223.SZ鱼跃医疗14.67%103.24%88.57%41.92%56.03%14.10%20.23%31.08%10.85%300562.SZ乐心医疗120.95%102.87%-18.08%24.13%24.96%0.83%3.86%6.08%2.22%002022.SZ科华生物1.51%100.95%99.44%45.09%56.47%11.38%14.91%25.96%11.05%688139.SH海尔生物253.53%87.78%-165.75%53.26%50.59%-2.67%18.42%27.97%9.55%600055.SH万东医疗1.99%66.87%64.88%45.39%54.19%8.80%14.30%19.99%5.69%300358.SZ楚天科技-89.77%61.19%150.95%29.68%33.90%4.21%1.76%3.46%1.70%300760.SZ迈瑞医疗27.34%45.31%17.97%65.21%66.84%1.62%29.68%33.39%3.72%688580.SH伟思医疗/19.87%/73.39%74.30%0.91%30.74%33.41%2.68%300273.SZ和佳医疗1.18%5.90%4.71%52.61%52.44%-0.17%9.97%13.52%3.55%688358.SH祥生医疗8.92%-0.48%-9.40%61.16%61.92%0.77%25.75%30.09%4.34%688277.SH天智航-U/-0.99%/80.20%71.55%-8.65%-110.57%-69.95%40.62%300753.SZ爱朋医疗20.92%-4.47%-25.40%72.64%65.99%-6.66%29.16%23.82%-5.34%300633.SZ开立医疗-74.52%-110.13%-35.61%65.71%64.47%-1.24%8.05%3.77%-4.27%002432.SZ九安医疗3.13%-541.44%-544.56%28.21%58.16%29.95%-17.76%27.06%44.82%20.25%86.26%66.01%47.66%53.51%5.85%18.59%23.68%5.09%证券代码证券简称扣非净利润增速毛利率净利率板块合计请务必阅读正文之后的重要声明部分-10-专题研究报告图表14：高值耗材板块业绩表现及盈利能力来源：Wind，中泰证券研究所图表15：高值耗材板块分季度归母净利润增速情况来源：Wind，中泰证券研究所19Q320Q3同比变化19Q320Q3同比变化19Q320Q3同比变化300246.SZ宝莱特26.55%474.31%447.76%38.66%53.03%14.36%10.41%29.25%18.84%300238.SZ冠昊生物-18.39%137.19%155.58%68.40%73.00%4.60%1.79%11.33%9.53%300453.SZ三鑫医疗37.16%122.15%84.99%33.43%37.35%3.93%8.61%13.20%4.58%300529.SZ健帆生物44.21%57.37%13.16%85.97%85.88%-0.09%42.90%47.57%4.67%688016.SH心脉医疗/46.79%/79.18%79.11%-0.07%45.45%49.49%4.03%688050.SH爱博医疗/42.87%/85.76%84.79%-0.97%34.47%37.56%3.09%300595.SZ欧普康视39.36%26.54%-12.82%79.99%80.50%0.51%45.99%46.98%0.98%002901.SZ大博医疗27.17%22.43%-4.74%85.68%85.78%0.10%40.62%39.17%-1.45%300003.SZ乐普医疗35.55%20.15%-15.41%72.64%69.74%-2.90%27.49%31.48%3.99%300653.SZ正海生物19.97%15.95%-4.02%93.78%92.69%-1.09%39.55%44.10%4.55%688085.SH三友医疗/5.87%/91.89%90.63%-1.26%28.72%29.69%0.97%688198.SH佰仁医疗29.47%4.85%-24.62%91.35%89.78%-1.57%44.65%47.14%2.49%300326.SZ凯利泰47.75%-17.36%-65.12%64.40%63.81%-0.59%25.99%24.91%-1.07%688029.SH南微医学/-28.05%/65.54%65.71%0.16%24.62%22.81%-1.80%688013.SH天臣医疗/-30.05%/59.78%59.24%-0.53%26.42%21.94%-4.48%688108.SH赛诺医疗7.18%-41.94%-49.12%83.50%79.96%-3.54%21.20%17.82%-3.38%688366.SH昊海生科-4.47%-61.70%-57.23%77.40%76.76%-0.64%23.78%11.48%-12.30%44.78%26.37%-18.41%72.27%71.29%-0.98%27.73%30.65%2.92%证券代码证券简称扣非净利润增速毛利率净利率板块合计证券代码证券简称19-1Q19-2Q19-3Q19-4Q20-1Q20-2Q20-3Q300246.SZ宝莱特-14.32%-24.25%76.11%-35.54%151.94%1629.12%169.33%688050.SH爱博医疗-80.10%74.70%152.04%300003.SZ乐普医疗92.22%13.03%36.91%50.32%-34.13%32.11%82.28%300238.SZ冠昊生物158.12%-154.48%-71.61%-2440.77%17.38%1339.67%81.74%688085.SH三友医疗-39.18%-12.52%76.52%300529.SZ健帆生物44.02%46.84%16.89%59.15%42.32%45.42%66.54%300453.SZ三鑫医疗-24.57%21.79%80.87%82.04%141.73%167.91%64.48%688016.SH心脉医疗76.48%100.67%32.42%52.28%52.13%688198.SH佰仁医疗13.72%546.84%-31.13%26.05%50.69%300653.SZ正海生物23.60%32.32%13.69%34.42%-28.22%48.69%40.85%300595.SZ欧普康视41.79%38.23%37.43%52.75%-24.81%36.05%32.68%688366.SH昊海生科-11.63%-137.33%-54.83%24.30%688029.SH南微医学58.59%161.70%-25.90%-22.91%23.09%002901.SZ大博医疗20.58%17.09%24.91%39.46%7.85%40.31%20.85%300326.SZ凯利泰48.88%30.44%41.77%-73.49%-30.79%-14.80%12.87%688108.SH赛诺医疗-3.94%-66.21%-2.98%-3.15%688013.SH天臣医疗-25.55%请务必阅读正文之后的重要声明部分-11-专题研究报告投资建议投资建议：医疗器械行业当前正处于黄金发展期，高壁垒化升级带来的进口替代以及消费化升级是目前国内医疗器械两大发展方向，疫情虽然短期对行业内各企业带来不同影响，但行业长期趋势并未发生改变。我们一方面建议重点关注具备强产品研发能力和技术实力的企业，包括迈瑞医疗、安图生物、南微医学、三友医疗、微创医疗等，另一方面建议重点关注具备强消费属性的产品企业，包括欧普康视、伟思医疗等。风险提示：产品市场推广不达预期风险，政策变化风险等。请务必阅读正文之后的重要声明部分-12-专题研究报告投资评级说明：评级说明股票评级买入预期未来6~12个月内相对同期基准指数涨幅在15%以上增持预期未来6~12个月内相对同期基准指数涨幅在5%~15%之间持有预期未来6~12个月内相对同期基准指数涨幅在-10%~+5%之间减持预期未来6~12个月内相对同期基准指数跌幅在10%以上行业评级增持预期未来6~12个月内对同期基准指数涨幅在10%以上中性预期未来6~12个月内对同期基准指数涨幅在-10%~+10%之间减持预期未来6~12个月内对同期基准指数跌幅在10%以上备注：评级标准为报告发布日后的6~12个月内公司股价（或行业指数）相对同期基准指数的相对市场表现。其中A股市场以沪深300指数为基准；新三板市场以三板成指（针对协议转让标的）或三板做市指数（针对做市转让标的）为基准；香港市场以摩根士丹利中国指数为基准，美股市场以标普500指数或纳斯达克综合指数为基准（另有说明的除外）。重要声明：中泰证券股份有限公司（以下简称“本公司”）具有中国证券监督管理委员会许可的证券投资咨询业务资格。本报告仅供本公司的客户使用。本公司不会因接收人收到本报告而视其为客户。本报告基于本公司及其研究人员认为可信的公开资料或实地调研资料，反映了作者的研究观点，力求独立、客观和公正，结论不受任何第三方的授意或影响。但本公司及其研究人员对这些信息的准确性和完整性不作任何保证，且本报告中的资料、意见、预测均反映报告初次公开发布时的判断，可能会随时调整。本公司对本报告所含信息可在不发出通知的情形下做出修改，投资者应当自行关注相应的更新或修改。本报告所载的资料、工具、意见、信息及推测只提供给客户作参考之用，不构成任何投资、法律、会计或税务的最终操作建议，本公司不就报告中的内容对最终操作建议做出任何担保。本报告中所指的投资及服务可能不适合个别客户，不构成客户私人咨询建议。市场有风险，投资需谨慎。在任何情况下，本公司不对任何人因使用本报告中的任何内容所引致的任何损失负任何责任。投资者应注意，在法律允许的情况下，本公司及其本公司的关联机构可能会持有报告中涉及的公司所发行的证券并进行交易，并可能为这些公司正在提供或争取提供投资银行、财务顾问和金融产品等各种金融服务。本公司及其本公司的关联机构或个人可能在本报告公开发布之前已经使用或了解其中的信息。本报告版权归“中泰证券股份有限公司”所有。未经事先本公司书面授权，任何人不得对本报告进行任何形式的发布、复制。如引用、刊发，需注明出处为“中泰证券研究所”，且不得对本报告进行有悖原意的删节或修改。","data":[{"id":"1","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"2020Q3（前三季度，下同）医疗器械板块上市公司收入增速52.62%（+31.98pp）","content_offset":["1020","1065"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["52.62%","1049","1055"],"indicator_element":{"时间":["2020Q3","1020","1026"],"行业":["医疗器械","1035","1039"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"净利润总额增长134.51%（+99.83pp）","content_offset":["1066","1090"],"indicators":[{"indicator_name":"净利润","indicator_value":["134.51%","1073","1080"],"indicator_element":{"时间":["2020Q3","1020","1026"],"行业":["医疗器械","1035","1039"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"扣非增长176.48%（+155.21pp）","content_offset":["1091","1113"],"indicators":[{"indicator_name":"扣非净利润","indicator_value":["176.48%","1095","1102"],"indicator_element":{"时间":["2020Q3","1020","1026"],"行业":["医疗器械","1035","1039"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"低值耗材：疫情下口罩、手套个股带动板块业绩高增长。低值耗材板块（19.84%，373.81%，506.13%，依次为2019年前三季度、2020年上半年、2020前三季度扣非增速，下同）","content_offset":["1200","1293"],"indicators":[{"indicator_name":"扣非净利润同比","indicator_value":["19.84%","1232","1238"],"indicator_element":{"时间":["2019年前三季度","1258","1267"],"行业":["低值耗材","1200","1204"]},"indicator_supplement":{"属性":""}},{"indicator_name":"扣非净利润同比","indicator_value":["373.81%","1239","1246"],"indicator_element":{"时间":["2020年上半年","1268","1276"],"行业":["低值耗材","1200","1204"]},"indicator_supplement":{"属性":""}},{"indicator_name":"扣非净利润同比","indicator_value":["506.13%","1247","1254"],"indicator_element":{"时间":["2020前三季度","1277","1285"],"行业":["低值耗材","1200","1204"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"Q3延续高增长态势，扣非利润同比增长506.13%（+486.29pp）；期间费用率下降，为16.15%（-9.19pp）；盈利能力大幅提高，毛利率53.60%（+13.40pp），净利率31.04%（+18.71pp）。","content_offset":["1293","1404"],"indicators":[{"indicator_name":"扣费净利润同比","indicator_value":["506.13%","1311","1318"],"indicator_element":{"时间":["Q3","1293","1295"],"行业":["低值耗材","1200","1204"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"Q3延续高增长态势，扣非利润同比增长506.13%（+486.29pp）；期间费用率下降，为16.15%（-9.19pp）；盈利能力大幅提高，毛利率53.60%（+13.40pp），净利率31.04%（+18.71pp）。","content_offset":["1293","1404"],"indicators":[{"indicator_name":"期间费用率","indicator_value":["16.15%","1339","1345"],"indicator_element":{"行业":["低值耗材","1200","1204"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"Q3延续高增长态势，扣非利润同比增长506.13%（+486.29pp）；期间费用率下降，为16.15%（-9.19pp）；盈利能力大幅提高，毛利率53.60%（+13.40pp），净利率31.04%（+18.71pp）。","content_offset":["1293","1404"],"indicators":[{"indicator_name":"毛利率","indicator_value":["53.60%（+13.40pp）","1367","1383"],"indicator_element":{"时间":["Q3","1293","1295"],"行业":["低值耗材","1200","1204"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"Q3延续高增长态势，扣非利润同比增长506.13%（+486.29pp）；期间费用率下降，为16.15%（-9.19pp）；盈利能力大幅提高，毛利率53.60%（+13.40pp），净利率31.04%（+18.71pp）。","content_offset":["1293","1404"],"indicators":[{"indicator_name":"净利率","indicator_value":["31.04%","1387","1393"],"indicator_element":{"时间":["Q3","1293","1295"],"行业":["低值耗材","1200","1204"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"体外诊断板块（39.30%，214.09%，208.36%）Q3延续高增长","content_offset":["1635","1672"],"indicators":[{"indicator_name":"扣费净利润同比","indicator_value":["39.30%","1642","1648"],"indicator_element":{"时间":["2019年前三季度","7471","7480"],"行业":["体外诊断","1635","1639"]},"indicator_supplement":{"属性":""}},{"indicator_name":"扣费净利润同比","indicator_value":["214.09%","1649","1656"],"indicator_element":{"时间":["2020年上半年","7481","7489"],"行业":["体外诊断","1635","1639"]},"indicator_supplement":{"属性":""}},{"indicator_name":"扣费净利润同比","indicator_value":["208.36%","1657","1664"],"indicator_element":{"时间":["2020前三季度","7490","7498"],"行业":["体外诊断","1635","1639"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"扣非利润同比增长208.36%（+169.06pp）；期间费用率下降，为25.58%（-6.81pp）；整体盈利能力提升，毛利率60.22%（+7.77pp），净利率29.08%（+13.03pp）","content_offset":["1673","1772"],"indicators":[{"indicator_name":"扣费净利润同比","indicator_value":["208.36%","1681","1688"],"indicator_element":{"行业":["体外诊断","1612","1616"],"时间":["Q3","1665","1667"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"扣非利润同比增长208.36%（+169.06pp）；期间费用率下降，为25.58%（-6.81pp）；整体盈利能力提升，毛利率60.22%（+7.77pp），净利率29.08%（+13.03pp）","content_offset":["1673","1772"],"indicators":[{"indicator_name":"期间费用率","indicator_value":["25.58%","1709","1715"],"indicator_element":{"行业":["体外诊断","1612","1616"],"时间":["Q3","1665","1667"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"扣非利润同比增长208.36%（+169.06pp）；期间费用率下降，为25.58%（-6.81pp）；整体盈利能力提升，毛利率60.22%（+7.77pp），净利率29.08%（+13.03pp）","content_offset":["1673","1772"],"indicators":[{"indicator_name":"毛利率","indicator_value":["60.22%","1737","1743"],"indicator_element":{"行业":["体外诊断","1612","1616"],"时间":["Q3","1665","1667"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"扣非利润同比增长208.36%（+169.06pp）；期间费用率下降，为25.58%（-6.81pp）；整体盈利能力提升，毛利率60.22%（+7.77pp），净利率29.08%（+13.03pp）","content_offset":["1673","1772"],"indicators":[{"indicator_name":"净利率","indicator_value":["29.08%","1756","1762"],"indicator_element":{"行业":["体外诊断","1612","1616"],"时间":["Q3","1665","1667"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"医疗设备板块（20.25%，88.29%，86.26%）","content_offset":["2029","2057"],"indicators":[{"indicator_name":"扣费净利润同比","indicator_value":["20.25%","2036","2042"],"indicator_element":{"时间":["2019年前三季度","7471","7480"],"行业":["医疗设备","2029","2033"]},"indicator_supplement":{"属性":""}},{"indicator_name":"扣费净利润同比","indicator_value":["88.29%","2043","2049"],"indicator_element":{"时间":["2020年上半年","7481","7489"],"行业":["医疗设备","2029","2033"]},"indicator_supplement":{"属性":""}},{"indicator_name":"扣费净利润同比","indicator_value":["86.26%","2050","2056"],"indicator_element":{"时间":["2020前三季度","7490","7498"],"行业":["医疗设备","2029","2033"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"Q3延续上半年的高增长，扣非利润同比增长86.26%（+66.01pp）；期间费用率略降，为26.57%（-2.42pp）；盈利能力增强，毛利率53.51%（+5.85pp），净利率23.68%（+5.09pp）","content_offset":["9941","10047"],"indicators":[{"indicator_name":"扣费净利润同比","indicator_value":["86.26%","9961","9967"],"indicator_element":{"行业":["医疗设备","9841","9845"],"时间":["Q3","9941","9943"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"Q3延续上半年的高增长，扣非利润同比增长86.26%（+66.01pp）；期间费用率略降，为26.57%（-2.42pp）；盈利能力增强，毛利率53.51%（+5.85pp），净利率23.68%（+5.09pp）","content_offset":["9941","10047"],"indicators":[{"indicator_name":"期间费用率","indicator_value":["26.57%","9987","9993"],"indicator_element":{"行业":["医疗设备","9841","9845"],"时间":["Q3","9941","9943"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"Q3延续上半年的高增长，扣非利润同比增长86.26%（+66.01pp）；期间费用率略降，为26.57%（-2.42pp）；盈利能力增强，毛利率53.51%（+5.85pp），净利率23.68%（+5.09pp）","content_offset":["9941","10047"],"indicators":[{"indicator_name":"毛利率","indicator_value":["53.51%","10013","10019"],"indicator_element":{"行业":["医疗设备","9841","9845"],"时间":["Q3","9941","9943"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"Q3延续上半年的高增长，扣非利润同比增长86.26%（+66.01pp）；期间费用率略降，为26.57%（-2.42pp）；盈利能力增强，毛利率53.51%（+5.85pp），净利率23.68%（+5.09pp）","content_offset":["9941","10047"],"indicators":[{"indicator_name":"净利率","indicator_value":["23.68%","10032","10038"],"indicator_element":{"行业":["医疗设备","9841","9845"],"时间":["Q3","9941","9943"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"高值耗材板块（44.78%，17.00%，26.37%）","content_offset":["2503","2531"],"indicators":[{"indicator_name":"扣费净利润同比","indicator_value":["44.78%","2510","2516"],"indicator_element":{"时间":["2019年前三季度","7471","7480"],"行业":["高值耗材","2503","2507"]},"indicator_supplement":{"属性":""}},{"indicator_name":"扣费净利润同比","indicator_value":["17.00%","2517","2523"],"indicator_element":{"时间":["2020年上半年","7481","7489"],"行业":["高值耗材","2503","2507"]},"indicator_supplement":{"属性":""}},{"indicator_name":"扣费净利润同比","indicator_value":["26.37%","2524","2530"],"indicator_element":{"时间":["2020前三季度","7490","7498"],"行业":["高值耗材","2503","2507"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"Q3增速同比放缓扣非利润同比26.37%（-18.41pp），但相比上半年恢复显著（+9.37pp）；期间费用率略降，为38.76%（-2.73pp）；盈利能力基本维持稳定，毛利率71.29%（-0.98pp），净利率30.65%（+2.92pp）。","content_offset":["-1","-1"],"indicators":[{"indicator_name":"扣费净利润同比","indicator_value":["26.37%","13","19"],"indicator_element":{"时间":["Q3","-1","1"],"行业":["高值耗材","1185","1189"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"Q3增速同比放缓扣非利润同比26.37%（-18.41pp），但相比上半年恢复显著（+9.37pp）；期间费用率略降，为38.76%（-2.73pp）；盈利能力基本维持稳定，毛利率71.29%（-0.98pp），净利率30.65%（+2.92pp）。","content_offset":["-1","-1"],"indicators":[{"indicator_name":"期间费用率","indicator_value":["38.76%","59","65"],"indicator_element":{"时间":["Q3","-1","1"],"行业":["高值耗材","1185","1189"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"Q3增速同比放缓扣非利润同比26.37%（-18.41pp），但相比上半年恢复显著（+9.37pp）；期间费用率略降，为38.76%（-2.73pp）；盈利能力基本维持稳定，毛利率71.29%（-0.98pp），净利率30.65%（+2.92pp）。","content_offset":["-1","-1"],"indicators":[{"indicator_name":"毛利率","indicator_value":["71.29%","89","95"],"indicator_element":{"时间":["Q3","-1","1"],"行业":["高值耗材","1185","1189"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"Q3增速同比放缓扣非利润同比26.37%（-18.41pp），但相比上半年恢复显著（+9.37pp）；期间费用率略降，为38.76%（-2.73pp）；盈利能力基本维持稳定，毛利率71.29%（-0.98pp），净利率30.65%（+2.92pp）。","content_offset":["-1","-1"],"indicators":[{"indicator_name":"净利率","indicator_value":["30.65%","108","114"],"indicator_element":{"时间":["Q3","-1","1"],"行业":["高值耗材","1185","1189"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"2020Q3（文中Q3均指前三季度）医疗器械板块上市公司收入增速52.62%（+31.98pp）","content_offset":["4691","4739"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["52.62%","4723","4729"],"indicator_element":{"时间":["2020Q3","4691","4697"],"行业":["医疗器械","4709","4713"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"净利润总额增长134.51%（+99.83pp）","content_offset":["1066","1090"],"indicators":[{"indicator_name":"净利润同比","indicator_value":["134.51%","1073","1080"],"indicator_element":{"时间":["2020Q3","1020","1026"],"行业":["医疗器械","1035","1039"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"扣非净利润增长176.48%（+155.21pp）","content_offset":["4765","4790"],"indicators":[{"indicator_name":"扣费净利润同比","indicator_value":["176.48%","4772","4779"],"indicator_element":{"时间":["2020Q3","4691","4697"],"行业":["医疗器械","4709","4713"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"2020Q3医疗器械板块销售费用率13.34%（-4.08pp），管理费用率（含研发费用）11.06%（-2.73pp），财务费用率0.84%（+0.48pp）","content_offset":["5875","5955"],"indicators":[{"indicator_name":"销售费用率","indicator_value":["13.34%","5892","5898"],"indicator_element":{"时间":["2020Q3","5875","5881"],"行业":["医疗器械","5881","5885"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"2020Q3医疗器械板块销售费用率13.34%（-4.08pp），管理费用率（含研发费用）11.06%（-2.73pp），财务费用率0.84%（+0.48pp）","content_offset":["5875","5955"],"indicators":[{"indicator_name":"管理费用率","indicator_value":["11.06%","5920","5926"],"indicator_element":{"时间":["2020Q3","5875","5881"],"行业":["医疗器械","5881","5885"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"2020Q3医疗器械板块销售费用率13.34%（-4.08pp），管理费用率（含研发费用）11.06%（-2.73pp），财务费用率0.84%（+0.48pp）","content_offset":["5875","5955"],"indicators":[{"indicator_name":"财务费用率","indicator_value":["0.84%","5941","5946"],"indicator_element":{"时间":["2020Q3","5875","5881"],"行业":["医疗器械","5881","5885"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"2020Q3医疗器械板块资产负债率30.84%（-2.57pp），基本保持稳定；应收账款周转率3.53次（+0.77次），存货周转率1.90次（-0.10次），","content_offset":["6051","6131"],"indicators":[{"indicator_name":"资产负债率","indicator_value":["30.84%","6068","6074"],"indicator_element":{"时间":["2020Q3","6051","6057"],"行业":["医疗器械","6057","6061"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"2020Q3医疗器械板块资产负债率30.84%（-2.57pp），基本保持稳定；应收账款周转率3.53次（+0.77次），存货周转率1.90次（-0.10次），","content_offset":["6051","6131"],"indicators":[{"indicator_name":"应收账款周转率","indicator_value":["3.53次","6098","6103"],"indicator_element":{"时间":["2020Q3","6051","6057"],"行业":["医疗器械","6057","6061"]},"indicator_supplement":{"属性":""}}]},{"id":"32","source_document":"医疗器械板块2020年三季报总结：海外防疫产品需求持续旺盛，国内恢复趋势良好.pdf","content":"2020Q3医疗器械板块资产负债率30.84%（-2.57pp），基本保持稳定；应收账款周转率3.53次（+0.77次），存货周转率1.90次（-0.10次），","content_offset":["6051","6131"],"indicators":[{"indicator_name":"存货周转率","indicator_value":["1.90次","6117","6122"],"indicator_element":{"时间":["2020Q3","6051","6057"],"行业":["医疗器械","6057","6061"]},"indicator_supplement":{"属性":""}}]}]}